‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

Dimitrios C. Mastellos,Anna M. Blom,E. Sander Connolly,Mohamed R. Daha,Brian V. Geisbrecht,Berhane Ghebrehiwet,Piet Gros,George Hajishengallis,V. Michael Holers,Markus Huber-Lang,Taroh Kinoshita,Tom Eirik Mollnes,Robert A. Montgomery,B. Paul Morgan,Bo Nilsson,Ruben Pio,Daniel Ricklin,Antonio M. Risitano,Ronald P. Taylor,Alberto Mantovani,John P. A. Ioannidis,John D. Lambris

‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

2019

Therapeutic innovations of potentially great clinical impact should embrace the overarching values of research accountability, data transparency and validation through the scientific peer-review process.

Keywords:

Transparency (graphic)
Drug development
Biology
Immunology
Accountability
Engineering ethics
data transparency
corporate innovation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations